Prothena

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Prothena and other ETFs, options, and stocks.

About PRTA

Prothena Corp. Plc is a clinical-stage neuroscience company, which engages in the discovery and development of novel therapies to change the course of devastating diseases. 

CEO
Gene G. Kinney
CEOGene G. Kinney
Employees
67
Employees67
Headquarters
Dublin, Dublin
HeadquartersDublin, Dublin
Founded
2012
Founded2012
Employees
67
Employees67

PRTA Key Statistics

Market cap
441.50M
Market cap441.50M
Price-Earnings ratio
-10.20
Price-Earnings ratio-10.20
Dividend yield
—
Dividend yield—
Average volume
568.21K
Average volume568.21K
High today
$8.62
High today$8.62
Low today
$8.30
Low today$8.30
Open price
$8.43
Open price$8.43
Volume
199.23K
Volume199.23K
52 Week high
$11.80
52 Week high$11.80
52 Week low
$7.73
52 Week low$7.73

Stock Snapshot

Prothena(PRTA) stock is priced at $8.60, giving the company a market capitalization of 441.5M. It carries a P/E multiple of -10.20.

On 2026-10-08, Prothena(PRTA) stock traded between a low of $8.30 and a high of $8.62. Shares are currently priced at $8.60, which is +3.6% above the low and -0.2% below the high.

Prothena(PRTA) shares are trading with a volume of 199.23K, against a daily average of 568.21K.

During the past year, Prothena(PRTA) stock moved between $7.73 at its lowest and $11.80 at its peak.

During the past year, Prothena(PRTA) stock moved between $7.73 at its lowest and $11.80 at its peak.

PRTA News

Zacks 2h
CRMD vs. PRTA: Which Stock Should Value Investors Buy Now?

Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both CorMedix (CRMD Quick QuoteCRMD - Free Report) and Prot...

CRMD vs. PRTA: Which Stock Should Value Investors Buy Now?
TipRanks 2d
Major Investor Makes Bold Move on Prothena Stock

New insider activity at Prothena ( (PRTA) ) has taken place on October 6, 2026. Significant shareholder William Scully has expanded his stake in Prothena, purch...

TipRanks 6d
Prothena Chief Development Officer Resigns for Partner Role

An update from Prothena ( (PRTA) ) is now available. On October 2, 2026, Prothena announced that its Chief Development Officer, Chad J. Swanson, Ph.D., has res...

Analyst ratings

50%

of 6 ratings
Buy
50%
Hold
33.3%
Sell
16.7%

People also own

Based on the portfolios of people who own PRTA. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.